Neuroendocrine gastro-enteropancreatic tumors-from eminence based to evidence-based medicine-A Scandinavian view

Scandinavian Journal of Gastroenterology

Volumn 50, Issue 6, 2015, Pages 727-739

  Öberg, Kjell ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cytokines; Genetics; Hormones and receptors; Immunology; Oncologyclinical; Small intestinal disorders

Indexed keywords

ALPHA INTERFERON; ANGIOPEPTIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; EVEROLIMUS; FLUOROURACIL; LUTETIUM 177; OCTREOTIDE; ONCOLYTIC VIRUS; PASIREOTIDE; RECOMBINANT ALPHA INTERFERON; STREPTOZOCIN; VAPREOTIDE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; EVIDENCE BASED MEDICINE; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; TELECOMMUNICATION; DISEASE MANAGEMENT; INTESTINAL NEOPLASMS; MORBIDITY; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PROCEDURES; SCANDINAVIA; STOMACH NEOPLASMS;

DISEASE MANAGEMENT; EVIDENCE-BASED MEDICINE; HUMANS; INTESTINAL NEOPLASMS; MORBIDITY; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; SCANDINAVIAN AND NORDIC COUNTRIES; STOMACH NEOPLASMS;

EID: 84929164917     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2015.1033001     Document Type: Article

References (108)

1. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008;9:61-72.
2. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-72.
3. Bosman FT, Carneiro F. WHO Classification of Tumours, pathology and genetics of tumours of the digestive system. Lyon: IARC Press; 2010.
4. Sundin A, VulliermeMP, Kaltsas G, Plockinger U. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations. Neuroendocrinology 2009;90:167-83.
5. Perri M, Erba P, Volterrani D, Lazzeri E, Boni G, Grosso M, et al. Octreo-SPECT/CT imaging for accurate detection and localization of suspected neuroendocrine tumors. Q J Nucl Med Mol Imaging 2008;52:323-33.
6. Krausz Y, Freedman N, Rubinstein R, Lavie E, Orevi M, Tshori S, et al. Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: comparison with (111) In-DTPA-octreotide (OctreoScan(R)). Mol Imaging Biol 2011;13:583-93.
7. Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007;48: 508-18.
8. Orlefors H, Sundin A, Garske U, Juhlin C, Oberg K, Skogseid B, et al. Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab 2005;90:3392-400.
9. Koopmans KP, Neels OC, Kema IP, Elsinga PH, Sluiter WJ, Vanghillewe K, et al. Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenylalanine and 11C-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol 2008;26:1489-95.
10. Binderup T, Knigge U, Loft A, Federspiel B, Kjaer A. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res 2010;16:978-85.
11. Taupenot L, Harper KL, O'Connor DT. The chromogranin-secretogranin family. N Engl J Med 2003; 348:1134-49.
12. Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV, Kidd M. Chromogranin A-biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol 2010;17:2427-43.
13. Welin S, Stridsberg M, Cunningham J, Granberg D, Skogseid B, Oberg K, et al. Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors. Neuroendocrinology 2009;89: 302-7.
14. de Herder WW. Biochemistry of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007;21:33-41.
15. Scarpa A, Mantovani W, Capelli P, Beghelli S, Boninsegna L, Bettini R, et al. Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol 2010;23:824-33.
16. Hentic O, Couvelard A, Rebours V, Zappa M, Dokmak S, Hammel P, et al. Ki-67 index, tumor differentiation, and extent of liver involvement are independent prognostic factors in patients with liver metastases of digestive endocrine carcinomas. Endocr Relat Cancer 2011;18: 51-9.
17. Kianmanesh R, O'Toole D, Sauvanet A, Ruszniewski P, Belghiti J. Surgical treatment of gastric, enteric pancreatic endocrine tumors. Part 2. treatment of hepatic metastases. J Chir 2005;142:208-19.
18. Eriksson J, Stalberg P, Nilsson A, Krause J, Lundberg C, Skogseid B, et al. Surgery and radiofrequency ablation for treatment of liver metastases from midgut and foregut carcinoids and endocrine pancreatic tumors. World J Surg 2008;32:930-8.
19. Ruszniewski P, Rougier P, Roche A, Legmann P, Sibert A, Hochlaf S, et al. Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Cancer 1993; 71:2624-30.
20. Vogl TJ, Gruber T, Naguib NN, Hammerstingl R, Nour-Eldin NE. Liver metastases of neuroendocrine tumors: treatment with hepatic transarterial chemotherapy using two therapeutic protocols. Ajr 2009;193:941-7.
21. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 2005;46 Suppl 1:62S-6S.
22. Modlin IM, Pavel M, Kidd M, Gustafsson BI. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 2010;31:169-88.
23. Oberg K. Interferon in the management of neuroendocrine GEP-tumors: a review. Digestion 2000;62:92-7.
24. Ekeblad S, Sundin A, Janson ET, Welin S, Granberg D, Kindmark H, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007;13:2986-91.
25. Turner NC, Strauss SJ, Sarker D, Gillmore R, Kirkwood A, Hackshaw A, et al. Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br J Cancer 2010;102:1106-12.
26. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514-23.
27. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364:501-13.
28. Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009;27:4656-63.
29. Caplin ME, Pavel M, Cwikla JB, Phan AT, Raderer M, Sedlackova E, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014;371: 224-33.
30. Yalow RS, Berson SA. Immunoassay of endogenous plasma insulin in man 1960. Obesity Res 1996;4:583-600.
31. Oberg K. Peptide hormone markers in endocrine gastrointestinal tumorsI. Acta Univers Upsal 1981;30:383.
32. Oberg K, Grimelius L, Lundqvist G, Lorelius LE. Update on pancreatic polypeptide as a specific marker for endocrine tumours of the pancreas and gut. Acta Med Scand 1981; 210:145-52.
33. Oberg K, Wide L, Bostrom H. HCG-alpha and HCG-beta subunits as tumour markers during therapy in a case with so-called "non-functioning" islet cell tumour. Acta Med Scand 1981;210:231-3.
34. Oberg K, Walinder O, Bostrom H, Lundqvist G, Wide L. Peptide hormone markers in screening for endocrine tumors in multiple endocrine adenomatosis type I. Am J Med 1982;73:619-30.
35. Wide L. Radioimmunoassays employing immunosorbents. Acta Endocrinol Suppl 1969;142:207-21.
36. Oberg K, Lundqvist G. Meal-stimulated and atropineinhibited secretion of pancreatic polypeptide in healthy subjects, members of MEA I families and patients with malignant endocrine tumours of the gastrointestinal tract. Regul Pept 1983;5:273-82.
37. Theodorsson-Norheim E, Oberg K, Rosell S, Bostrom H. Neurotensinlike immunoreactivity in plasma and tumor tissue from patients with endocrine tumors of the pancreas and gut. Gastroenterology 1983;85:881-9.
38. Norheim I, Theodorsson-Norheim E, Brodin E, Oberg K, Lundqvist G, Rosell S. Antisera raised against eledoisin and kassinin detect elevated levels of immunoreactive material in plasma and tumor tissues from patients with carcinoid tumors. Regul Pept 1984;9:245-57.
39. Norheim I, Wilander E, Oberg K, Theodorsson-Norheim E, Lundqvist ML, Lindgren P, et al. Tachykinin production by carcinoid tumours in culture. Eur J Cancer Clin Oncol 1987;23:689-95.
40. Norheim I, Theodorsson-Norheim E, Brodin E, Oberg K. Tachykinins in carcinoid tumors: their use as a tumor marker and possible role in the carcinoid flush. J Clin Endocrinol Metab 1986;63:605-12.
41. Oberg K, Lundqvist G, Wide L. Treatment of the carcinoid syndrome with SMS 201-995;a somatostatin analogue. Scand J Gastroenterol 1986;119:191-2.
42. Oberg K, Theodorsson-Norheim E, Norheim I. Motilin in plasma and tumor tissues from patients with the carcinoid syndrome. Possible involvement in the increased frequency of bowel movements. Scand J Gastroenterol 1987;22:1041-8.
43. Eriksson B, Arnberg H, Oberg K, Hellman U, Lundqvist G, Wernstedt C, et al. A polyclonal antiserum against chromogranin A and B-a new sensitive marker for neuroendocrine tumours. Acta Endocrinol 1990;122: 145-55.
44. O'Connor DT, Deftos LJ. Secretion of chromogranin A by peptide-producing endocrine neoplasms. N Engl J Med 1986;314:1145-51.
45. Eriksson B, Arnberg H, Oberg K, Hellman U, Lundqvist G, Wernstedt C, et al. Chromogranins-new sensitive markers for neuroendocrine tumors. Acta Oncol 1989;28:325-9.
46. Blaschko H, Comline RS, Schneider FH, Silver M, Smith AD. Secretion of a chromaffin granule protein, chromogranin, from the adrenal gland after splanchnic stimulation. Nature 1967;215:58-9.
47. Stridsberg M, Hellman U, Wilander E, Lundqvist G, Hellsing K, Oberg K. Fragments of chromogranin A are present in the urine of patients with carcinoid tumours: development of a specific radioimmunoassay for chromogranin A and its fragments. J Endocrinol 1993;139:329-37.
48. Larsson L, Alumets J, Eriksson B, Hakansson R, Lunqvist G, Öberg K, et al. Antiserum directed against both chromogranin A and B (CAB) is a general marker for peptide hormone producing endocrine cells and toumors. Endoc Pathol 1992;3:14-22.
49. Lundin L, Norheim I, Landelius J, Oberg K, Theodorsson-Norheim E. Carcinoid heart disease: relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities. Circulation 1988;77:264-9.
50. Thorson A, Biorck G, Bjorkman G, Waldenstrom J. Malignant carcinoid of the small intestine with metastases to the liver, valvular disease of the right side of the heart (pulmonary stenosis and tricuspid regurgitation without septal defects), peripheral vasomotor symptoms, bronchoconstriction, and an unusual type of cyanosis; a clinical and pathologic syndrome. Am Heart J 1954;47:795-817.
51. Funa K, Papanicolaou V, Juhlin C, Rastad J, Akerstrom G, Heldin CH, et al. Expression of platelet-derived growth factor beta-receptors on stromal tissue cells in human carcinoid tumors. Cancer Res 1990;50:748-53.
52. Waltenberger J, Lundin L, Oberg K, Wilander E, Miyazono K, Heldin CH, et al. Involvement of transforming growth factor-beta in the formation of fibrotic lesions in carcinoid heart disease. Am J Pathol 1993;142:71-8.
53. Chaudhry A, Oberg K, Wilander E. A study of biological behavior based on the expression of a proliferating antigen in neuroendocrine tumors of the digestive system. Tumour Biol 1992;13:27-35.
54. Cui T, Tsolakis AV, Li SC, Cunningham JL, Lind T, Oberg K, et al. Olfactory receptor 51E1 protein as a potential novel tissue biomarker for small intestine neuroendocrine carcinomas. Eur J Endocrinol 2013;168:253-61.
55. Li SC, Essaghir A, Martijn C, Lloyd RV, Demoulin JB, Oberg K, et al. Global microRNA profiling of welldifferentiated small intestinal neuroendocrine tumors. Mod Pathol 2013;26:685-96.
56. Hemmingsson A, Lindgren PG, Lorelius LE, Oberg K. Diagnosis of endocrine gastrointestinal tumours. Acta Radiol Diagn 1981;22:657-62.
57. Andersson T, Eriksson B, Hemmingsson A, Lindgren PG, Oberg K. Angiography, computed tomography, magnetic resonance imaging and ultrasonography in detection of liver metastases from endocrine gastrointestinal tumours. Acta Radiol 1987;28:535-9.
58. Andersson T, Eriksson B, Lindgren PG, Wilander E, Oberg K. Percutaneous ultrasonography-guided cutting biopsy from liver metastases of endocrine gastrointestinal tumors. Ann Sur 1987;206:728-32.
59. Eriksson B, Bergstrom M, Lilja A, Ahlstrom H, Langstrom B, Oberg K. Positron emission tomography (PET) in neuroendocrine gastrointestinal tumors. Acta Oncol (Madr) 1993;32:189-96.
60. Westlin JE, Janson ET, Arnberg H, Ahlstrom H, Oberg K, Nilsson S. Somatostatin receptor scintigraphy of carcinoid tumours using the 111In-DTPA-D-Phe1]-octreotide. Acta Oncol (Madr) 1993;32:783-6.
61. Westlin JE, Ahlstrom H, Yla-Jaaski J, Oberg K, Nilsson S. Three-dimensional OctreoScan111 SPECT of abdominal manifestation of neuroendocrine tumours. Acta Oncol (Madr) 1993;32:171-6.
62. Kalkner KM, Janson ET, Nilsson S, Carlsson S, Oberg K, Westlin JE. Somatostatin receptor scintigraphy in patients with carcinoid tumors: comparison between radiology uptake and tumor markers. Cancer Res 1995;55:5801s-4s.
63. Janson ET, Westlin JE, Eriksson B, Ahlstrom H, Nilsson S, Oberg K. 111In-DTPA-D-Phe1]octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment. Eur J Endocrinol 1994; 131:577-81.
64. Ahlstrom H, Eriksson B, Bergstrom M, Bjurling P, Langstrom B, Oberg K. Pancreatic neuroendocrine tumors: diagnosis with PET. Radiology 1995;195:333-7.
65. Orlefors H, Sundin A, Garske U, Juhlin C, Oberg K, Skogseid B, et al. Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab 2005;90:3392-400.
66. Eriksson B, Bergstrom M, Orlefors H, Sundin A, Oberg K, Langstrom B. Use of PET in neuroendocrine tumors. In vivo applications and in vitro studies. Q J Nucl Med 2000;44:68-76.
67. Sundin A, Eriksson B, Bergstrom M, Langstrom B, Oberg K, Orlefors H. PET in the diagnosis of neuroendocrine tumors. Ann N Y Acad Sci 2004;1014: 246-57.
68. Eriksson B, Orlefors H, Oberg K, Sundin A, Bergstrom M, Langstrom B. Developments in PET for the detection of endocrine tumours. Best Pract Res Clin Endocrinol Metab 2005;19:311-24.
69. Oberg K. Molecular imaging radiotherapy: theranostics for personalized patient management of neuroendocrine tumors (NETs). Theranostics 2012;2:448-58.
70. Skogseid B, Oberg K, Benson L, Lindgren PG, Lorelius LE, Lundquist G, et al. A standardized meal stimulation test of the endocrine pancreas for early detection of pancreatic endocrine tumors in multiple endocrine neoplasia type 1 syndrome: five years experience. J Clin Endocrinol Metab 1987;64:1233-40.
71. Larsson C, Skogseid B, Oberg K, Nakamura Y, Nordenskjold M. Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 1988;332:85-7.
72. Oberg K, Bostrom H, Fahrenkrug J, Dymling JF, Shaffalitsky de Muckadell OB, Lundqvist G. Streptozotocin treatment of a pancreatic tumour producing VIP and gastrin associated with Verner-Morrison syndrome. Acta Med Scand 1979;206:223-7.
73. Oberg K, Lundqvist G, Boström H. The effect of Streptozotocin in the treatment of endocrine pancreatic tumors and carcinoids. In Agrewall MK, editor. Streptozotocin. North Holland: Elsevier; 1982.
74. Oberg K, Funa K, Alm G. Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with midgut carcinoid tumors and carcinoid syndrome. N Engl J Med 1983;309:129-33.
75. Funa K, Alm GV, Ronnblom L, Oberg K. Evaluation of the natural killer cell-interferon system in patients with mid-gut carcinoid tumours treated with leucocyte interferon. Clin Exp Immunol 1983;53:716-24.
76. Wilander E, Bengtsson A, Norheim I, Oberg K. Interferoninduced nuclear DNA alterations in malignant carcinoid tumors in vivo. J Natl Cancer Inst 1986;76:429-33.
77. Eriksson B, Oberg K, Alm G, Karlsson A, Lundqvist G, Magnusson A, et al. Treatment of malignant endocrine pancreatic tumors with human leukocyte interferon. Cancer Treat Rep 1987;71:31-7.
78. Burman P, Totterman TH, Oberg K, Karlsson FA. Thyroid autoimmunity in patients on long term therapy with leukocyte-derived interferon. J Clin Endocrinol Metab 1986;63:1086-90.
79. Oberg K, Jakobsson A, Gustafsson G, Wilander E, Lundqvist G, Stridsberg M. WDHA-syndrome due to a VIP and NPY producing ganglioneuroblastoma. Treatment with SMS 201-995, a somatostatin analogue. Scand J Gastroenterol 1986;Vol 21:228-9.
80. Oberg K, Eriksson B, Norheim I. Treatment of malignant neuroendocrine gut and pancreatic tumors with the somatostatin analogue SMS 201-995. Proceedings of Concensus Meeting on Somatostatin analogue SMS 201-995, Sandoz. Phoenix, Arizona, USA; 1987. pp 89-92.
81. Eriksson B, Oberg K, Andersson T, Lundqvist G, Wide L, Wilander E. Treatment of malignant endocrine pancreatic tumors with a new long-acting somatostatin analogue, SMS 201-995. Scand J Gastroenterol 1988;23:508-12.
82. Oberg K, Norheim I, Theodorsson E, Ahlman H, Lundqvist G, Wide L. The effects of octreotide on basal and stimulated hormone levels in patients with carcinoid syndrome. J Clin Endocrinol Metab 1989;68: 796-800.
83. Oberg K, Alm GV. Development of neutralizing interferon antibodies after treatment with recombinant interferonalpha 2b in patients with malignant carcinoid tumors. J Interferon Res 1989;9:S45-9.
84. Oberg K, Alm G, Magnusson A, Lundqvist G, Theodorsson E, Wide L, et al. Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity. J Natl Cancer Inst 1989;81: 531-5.
85. Ronnblom LE, Alm GV, Oberg KE. Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumour. J Intern Med 1990;227:207-10.
86. Eriksson B, Skogseid B, Lundqvist G, Wide L, Wilander E, Oberg K. Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors. Cancer 1990;65:1883-90.
87. Makridis C, Oberg K, Juhlin C, Rastad J, Johansson H, Lorelius LE, et al. Surgical treatment of mid-gut carcinoid tumors. World J Surg 1990;14:377-83.
88. Grander D, Oberg K, Lundqvist ML, Janson ET, Eriksson B, Einhorn S. Interferon-induced enhancement of 2',5'-oligoadenylate synthetase in mid-gut carcinoid tumours. Lancet 1990;336:337-40.
89. Ronnblom LE, Alm GV, Oberg KE. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med 1991;115:178-83.
90. Tiensuu Janson EM, Ahlstrom H, Andersson T, Oberg KE. Octreotide and interferon alfa: a new combination for the treatment of malignant carcinoid tumours. Eur J Cancer 1992;28A:1647-50.
91. Janson ET, Oberg K. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol (Madr) 1993;32:225-9.
92. Janson ET, Holmberg L, Stridsberg M, Eriksson B, Theodorsson E, Wilander E, et al. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 1997;8:685-90.
93. Eriksson B, Janson ET, Bax ND, Mignon M, Morant R, Opolon P, et al. The use of new somatostatin analogues, lanreotide and octastatin, in neuroendocrine gastrointestinal tumours. Digestion 1996;57:77-80.
94. Eriksson B, Renstrup J, Imam H, Oberg K. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects. Ann Oncol 1997;8:1041-4.
95. Eriksson BK, Larsson EG, Skogseid BM, Lofberg AM, Lorelius LE, Oberg KE. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 1998;83:2293-301.
96. Afargan M, Janson ET, Gelerman G, Rosenfeld R, Ziv O, Karpov O, et al. Novel long-acting somatostatin analog with endocrine selectivity: potent suppression of growth hormone but not of insulin. Endocrinology 2001;142:477-86.
97. Fjallskog ML, Granberg DP, Welin SL, Eriksson C, Oberg KE, Janson ET, et al. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 2001;92:1101-7.
98. Wymenga AN, Eriksson B, Salmela PI, Jacobsen MB, Van Cutsem EJ, Fiasse RH, et al. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol 1999;17:1111.
99. Welin SV, Janson ET, Sundin A, Stridsberg M, Lavenius E, Granberg D, et al. High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours. Eur J Endocrinol 2004;151:107-12.
100. Bushnell DL Jr, O'Dorisio TM, O'Dorisio MS, Menda Y, Hicks RJ, Van Cutsem E, et al. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol 2010; 28:1652-9.
101. Leja J, Dzojic H, Gustafson E, Oberg K, Giandomenico V, Essand M. A novel chromogranin-A promoter-driven oncolytic adenovirus for midgut carcinoid therapy. Clin Cancer Res 2007;13:2455-62.
102. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514-23.
103. Pavel ME, Hainsworth JD, Baudin E, Peeters M, Horsch D, Winkler RE, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011;378:2005-12.
104. Ekeblad S, Skogseid B, Dunder K, Oberg K, Eriksson B. Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res 2008;14:7798-803.
105. Welin S, Sorbye H, Sebjornsen S, Knappskog S, Busch C, Oberg K. Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer 2011;117: 4617-22.
106. Norlen O, Stalberg P, Oberg K, Eriksson J, Hedberg J, Hessman O, et al. Long-Term Results of Surgery for Small Intestinal Neuroendocrine Tumors at a Tertiary Referral Center. World J Surg 2012;36:1419-31.
107. Kvols LK, Oberg KE, O'Dorisio TM, Mohideen P, de Herder WW, Arnold R, et al. Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocr Relat Cancer 2012;19:657-66.
108. Oberg K, Knigge U, Kwekkeboom D, Perren A. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23:vii124-30.